124 related articles for article (PubMed ID: 10411122)
1. Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits.
Toubert ME; Cyna-Gorse F; Zagdanski AM; Noel-Wekstein S; Cattan P; Billotey C; Sarfati E; Rain JD
Thyroid; 1999 Jun; 9(6):591-7. PubMed ID: 10411122
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
3. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
4. MRI versus ¹³¹I whole-body scintigraphy for the detection of lymph node recurrences in differentiated thyroid carcinoma.
Mihailovic J; Prvulovic M; Ivkovic M; Markoski B; Martinov D
AJR Am J Roentgenol; 2010 Nov; 195(5):1197-203. PubMed ID: 20966328
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
6. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
7. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.
Seiboth L; Van Nostrand D; Wartofsky L; Ousman Y; Jonklaas J; Butler C; Atkins F; Burman K
Thyroid; 2008 Feb; 18(2):103-11. PubMed ID: 18279011
[TBL] [Abstract][Full Text] [Related]
8. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.
Travagli JP; Cailleux AF; Ricard M; Baudin E; Caillou B; Parmentier C; Schlumberger M
J Clin Endocrinol Metab; 1998 Aug; 83(8):2675-80. PubMed ID: 9709930
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
11. False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinoma.
Schmidt M; Dietlein M; Schröder U; Schicha H
Clin Nucl Med; 2006 Nov; 31(11):716-7. PubMed ID: 17053394
[TBL] [Abstract][Full Text] [Related]
12. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
13. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
14. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
15. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management.
Song H; Mosci C; Akatsu H; Basina M; Dosiou C; Iagaru A
Clin Nucl Med; 2018 Oct; 43(10):705-709. PubMed ID: 30153149
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
[TBL] [Abstract][Full Text] [Related]
19. Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.
Mohan V; Jones RC; Drake AJ; Daly PL; Shakir KM
Thyroid; 2005 Feb; 15(2):170-5. PubMed ID: 15753678
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
